Thank you for donating!

You can donate using the following services.

News

  1. 05.03.20

    INHERITED METABOLIC DISEASE AND CORONAVIRUS (COVID-19) Advice for patients / parents / guardians

    Advice for patients / parents / guardians regarding Coronavirus (COVID-19)...

    Read more
  2. 04.03.20

    IntraBio Extension Phase for Niemann-Pick C Accepted in United States

    Oxford, UK / IntraBio Inc. is pleased to announce that the Extension Phase for the IB1001-201 Clinical Trial has been accepted by the FDA (US Food and Drug Administration). The Extension Phase has also been previously approved by all European countries in which the trial is being conducted, including Germany, Slovakia, Spain, and the UK.

    Read more
  3. 02.03.20

    Cyclo Therapeutics Announces Positive Feedback from FDA on its Pivotal Trial Design for Trappsol® Cyclo™ for Niemann-Pick Disease Type C1

    Company next plans to meet with European Medicines Agency in second quarter 2020...

    Read more
  4. 20.02.20

    Cyclo Therapeutics Announces Completion of Enrollment in its Phase I/II Trial to Evaluate Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

    Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease, today announced that it has completed patient enrollment in its Phase I/II trial to evaluate the safety, tolerability, and efficacy of Trappsol® Cyclo™ administered intravenously to Niemann-Pick Disease Type C1 (NPC1) patients...

    Read more
  5. 12.02.20

    Last Patient Last Visit in Cyclo Therapeutics’ Phase I Trial in Niemann-Pick Type C

    GAINESVILLE, FL – (Businesswire) – February 11, 2020 – Cyclo Therapeutics, Inc. (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that the last patient has undergone the final assessment in its Phase I trial to evaluate the safety and tolerability of Trappsol® Cyclo™ administered intravenously to NPC patients.

    Read more